Astellas Pharma Inc. (TYO:4503)
Japan · Delayed Price · Currency is JPY | Market Cap | 2.59T |
| Revenue (ttm) | 1.91T |
| Net Income (ttm) | 50.75B |
| Shares Out | 1.79B |
| EPS (ttm) | 28.24 |
| PE Ratio | 51.29 |
| Forward PE | 18.40 |
| Dividend | 78.00 (5.38%) |
| Ex-Dividend Date | Sep 29, 2025 |
| Volume | 4,456,500 |
| Average Volume | 6,181,660 |
| Open | 1,457.00 |
| Previous Close | 1,452.00 |
| Day's Range | 1,444.00 - 1,461.50 |
| 52-Week Range | 1,243.50 - 1,835.00 |
| Beta | 0.13 |
| RSI | 62.61 |
| Earnings Date | Aug 1, 2025 |
About Astellas Pharma
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAG... [Read more]
Financial Performance
In 2024, Astellas Pharma's revenue was 1.91 trillion, an increase of 19.25% compared to the previous year's 1.60 trillion. Earnings were 50.75 billion, an increase of 197.72%.
Financial StatementsNews
Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Companies Program"
- Supporting Korean Startups' Drug Discovery Research and Global Expansion - - First Pharmaceutical Company from Japan to Actively Support the Operation of the Program - TOKYO , July 17, 2025 /PRNewsw...
China hands 3-1/2-year prison sentence to Astellas' Japanese employee, Nikkei says
TOKYO (Reuters) -A Beijing court on Wednesday sentenced a Japanese employee of Astellas Pharma to 3-1/2 years in prison, the Nikkei newspaper reported, citing the Japanese ambassador to China. Chinese...
China jails Japanese businessman for espionage, embassy says
Astellas Pharma employee sentenced to three and a half years in prison, Japan's embassy in Beijing says.
Chinese court sentences a Japanese man to more than 3 years in prison on espionage charges
A Japanese business person was sentenced Wednesday to three and a half years in prison in China on espionage charges, according to the Japanese embassy in Beijing. Japan's Kyodo News Agency described ...
Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (OTC: ALPMF) (OTC: ALPMY) on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtan...
Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan
Accelerating the Growth of Globally Active Drug-Discovery Startups from Japan TOKYO , June 13, 2025 /PRNewswire/ -- Mitsubishi Research Institute, Inc. ("MRI") and Astellas Pharma Inc. ("Astellas") to...
Lupin shares in focus after US Court rejects plea in Astellas Patent case
Lupin shares were in focus after a U.S. District Court rejected the proposal filed by generic drugmakers Lupin and Zydus in a legal dispute with Astellas Pharma over the interpretation of the ‘189 pat...
Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2
- Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW27011 - - XNW27011 has demonstrated encouraging ...
Astellas Announces Second Annual Patient Advocacy Organization (PAO) Action Week™ To Empower Patients and Caregivers
Building on a successful inaugural year, the initiative sponsored by Astellas' Patient Centricity team continues to connect individuals with vital resources and support from patient advocacy organizat...
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatme...
Astellas and MBC BioLabs Announce the 2025 Astellas Future Innovator Prize Awarded to DeepSeq.AI & Serna Bio
Both companies have earned a year-long opportunity for access to a distinguished life-science incubator in San Francisco along with the invaluable expertise provided by Astellas to advance their resea...
Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses
ARVO and RWC abstracts feature analyses on biomarkers, mechanism of disease, patient experience and other data from IZERVAY ™ (avacincaptad pegol intravitreal solution) pivotal studies TOKYO , May 1,...
Astellas Pharma Inc. (ALPMF) Q4 2024 Earnings Call Transcript
Astellas Pharma reports FY results
Zydus Lifesciences confirms losing US patent case to Astellas in mirabegron litigation
Zydus Lifesciences Ltd announced that the United States District Court for the District of Delaware has ruled in favor of Astellas Pharma Inc., upholding the validity of the Japanese drugmaker’s US Pa...
Zydus down 5%, Lupin down nearly 4% as US court orders withdrawal of Myrbetriq drug
Shares of Zydus Lifesciences and Lupin plunged sharply on April 16 after both companies lost a patent litigation case related to the bladder treatment drug Myrbetriq in the United States. The US Feder...
Singlera Genomics Presented Non-Invasive Testicular Toxicity Detection with Astellas at 2025 SOT Meeting
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Singlera Genomics presented results showing a refined approach to detect drug-induced testicular toxicity using Singlera's cell-free DNA methylation techn...
Astellas Pharma: Raising New, As Yet Unanswered Questions In Stomach Cancer And Moving Their Pipeline Forward
Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing
- Joint venture will aim to develop a cell therapy manufacturing platform through robotics and will offer access to startups and academic institutions - TOKYO , March 5, 2025 /PRNewswire/ -- Astellas ...
Astellas and MBC BioLabs Announce the Sixth Annual Astellas Future Innovator Prize
Awardees win a year of access to a prestigious life-science incubator in San Francisco and to Astellas expertise to further their research Award helps biotech start-ups accelerate early drug discovery...
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
IZERVAY dosing approved beyond 12 months TOKYO , Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Ad...
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
On Monday, Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (OTC: ALPMF) (OTC: ALPMY) released additional follow-up results from the Phase 3 EV-302 trial (also known as KEYNOTE-A39) of Padcev (enfo...
Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line treatment of l...
Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript
Astellas Pharma Inc. 2024 Q3 - Results - Earnings Call Presentation
The following slide deck was published by Astellas Pharma Inc.